Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Interest & Investment Income came in at $229.0 million in Q1 2026, down 31.02% year-on-year from $332.0 million in Q1 2025, and down 3.38% quarter-over-quarter from $237.0 million in Q4 2025.
Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Interest & Investment Income across 18 years of filings, most recently posting $229.0 million for Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $229.0 million, down 31.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $953.0 million (down 26.69% YoY), and the FY2025 annual result was $1.1 billion, down 20.72% from the prior year.
- Interest & Investment Income came in at $229.0 million for Q1 2026 at Johnson & Johnson, down from $237.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $450.0 million in Q1 2023 to a low of $22.0 million in Q2 2022.
- The 5-year median for Interest & Investment Income is $281.0 million (2024), against an average of $268.5 million.
- Across the five-year window, Interest & Investment Income surged 1053.85% in 2022 and tumbled 34.18% in 2025, its largest moves.
- Johnson & Johnson's Interest & Investment Income stood at $150.0 million in 2022, then soared by 142.0% to $363.0 million in 2023, then dropped by 22.59% to $281.0 million in 2024, then slipped by 15.66% to $237.0 million in 2025, then slipped by 3.38% to $229.0 million in 2026.
- The last three Interest & Investment Income figures came in at $229.0 million (Q1 2026), $237.0 million (Q4 2025), and $227.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 229.00 Mn |
| Dec 28, 2025 | 237.00 Mn |
| Sep 28, 2025 | 227.00 Mn |
| Jun 29, 2025 | 260.00 Mn |
| Mar 30, 2025 | 332.00 Mn |
| Dec 29, 2024 | 281.00 Mn |
| Sep 29, 2024 | 292.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 364.00 Mn |
| Dec 31, 2023 | 363.00 Mn |
| Oct 1, 2023 | 374.00 Mn |
| Jul 2, 2023 | 326.00 Mn |
| Apr 2, 2023 | 198.00 Mn |
| Jan 1, 2023 | 450.00 Mn |
| Oct 2, 2022 | 150.00 Mn |
| Jul 3, 2022 | 64.00 Mn |
| Apr 3, 2022 | 22.00 Mn |
| Oct 3, 2021 | 13.00 Mn |
| Jul 4, 2021 | 12.00 Mn |
| Apr 4, 2021 | 15.00 Mn |